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Abstract: Introduction: We aimed to determine whether KRAS and BRAF mutant colorectal cancer (CRC) cells ex-
hibit distinct sensitivities to the multi-target angiokinase inhibitor, TKI258 (dovitinib). Materials and methods: We 
screened 10 CRC cell lines by using receptor tyrosine kinase (RTK) array to identify activated RTKs. MTT assays, 
anchorage-independent colony-formation assays, and immunoblotting assays were performed to evaluate the in 
vitro anti-tumor effects of TKI258. In vivo efficacy study followed by pharmacodynamic evaluation was done. Re-
sults: Fibroblast Growth Factor Receptor 1 (FGFR1) and FGFR3 were among the most highly activated RTKs in CRC 
cell lines. In in vitro assays, the BRAF mutant HT-29 cells were more resistant to the TKI258 than the KRAS mutant 
LoVo cells. However, in xenograft assays, TKI258 equally delayed the growth of tumors induced by both cell lines. 
TUNEL assays showed that the apoptotic index was unchanged following TKI258 treatment, but staining for Ki-67 
and CD31 was substantially reduced in both xenografts, implying an anti-angiogenic effect of the drug. TKI258 
treatment was effective in delaying CRC tumor growth in vivo regardless of the KRAS and BRAF mutation status. 
Conclusions: Our results identify FGFRs as potential targets in CRC treatment and suggest that combined targeting 
of multiple RTKs with TKI258 might serve as a novel approach to improve outcome of patients with CRC.
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Introduction 
Colorectal cancer (CRC) is the third-most com-
monly diagnosed cancer in males and the sec-
ond-most commonly diagnosed cancer in fe- 
males worldwide [1]. Moreover, CRC incidence 
is increasing rapidly in several historically low-
risk countries such as countries in Eastern Asia 
and Eastern Europe [2]. Because conventional 
anti-cancer drugs are not adequate for improv-
ing CRC-treatment outcome, we must under-
stand the molecular biology of colon cancer 
and identify relevant molecular targets to bio-
logically modulate the cancer.
Numerous inhibitors that target various recep-
tor tyrosine kinases (RTKs) have been con-
firmed to inhibit tumor survival and angiogene-
sis in preclinical trial models of CRC [3-5]. 
Bevacizumab, a humanized monoclonal anti-
body that targets vascular endothelial growth 
factor A (VEGF-A) was approved for first- or sec-
ond-line use in metastatic CRC, in combination 
with conventional chemotherapy [6-8]. Further- 
more, certain epidermal growth factor receptor 
(EGFR)-inhibiting monoclonal antibodies such 
as cetuximab and panitumumab showed mod-
est efficacy in monotherapy or combination 
therapy [9-12]. However, the results of several 
studies in which these RTK inhibitors were used 
on CRC patients showed limited effect, implying 
that more effective therapeutic RTK inhibitors 
are required.
Fibroblast growth factors (FGFs), which promote 
angiogenesis and tumor growth by binding to 
tyrosine kinase. FGF receptors (FGFRs), are 
reported to be overexpressed in CRC patients 
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[13, 14]. FGFR genes have been reported to 
potentially promote tumor growth and invasion 
in CRC [13, 15, 16], and FGFR signals were 
implicated in the intrinsic resistance to EGFR 
inhibitors [17] in non-small cell lung cancer 
(NSCLC). Given these results, FGFR inhibitors 
are considered one of the potential RTK inhibi-
tors that can be used to treat CRC patients; this 
is not only because FGFR is overexpressed in 
CRC, but also because this treatment might 
help overcome the resistance to EGFR inhi- 
bitors.
TKI258 is an orally active small molecule that 
potently inhibits the activity of multiple RTKs 
including FGFRs, platelet-derived growth factor 
receptors (PDGFRs), and VEGF receptors (VE- 
GFRs), which participate in tumor growth, sur-
vival, angiogenesis, and vascular development 
[18] through both direct and indirect mecha-
nisms. Inhibiting multiple angiokinases - mainly 
FGFRs - led to the suppression of their down-
stream signaling including signaling by RAS-
RAF-MAPK molecules and PI3K-AKT related 
molecules that are mainly involved in cell prolif-
eration, cell survival, and tumor invasion [19].
Mutations in the v-Ki-ras2 Kirsten rat sarcoma 
viral oncogene homolog (KRAS), which occur in 
approximately 40% of CRC patients, is consid-
ered one of the major negative predictive fac-
tors in the treatment response in patients 
receiving EGFR-directed antibodies [20, 21]. In 
the absence of KRAS mutations, resistance to 
EGFR inhibitors has been reported to be poten-
tially caused by genetic alterations of mole-
cules related to RAS-RAF-MAPK signaling [19, 
22]. Furthermore, mutation in v-raf murine sar-
coma viral oncogene homolog B1 (BRAF) 
appears to mediate cetuximab resistance in 
the absence of KRAS mutation [23, 24], and. 
BRAF mutations have been widely reported to 
occur only in KRAS-negative colon carcinomas, 
suggesting that BRAF/KRAS activating muta-
tions might be alternative genetic events in 
CRC [26-28]. Recently, the mutually exclusive 
BRAF/KRAS mutation status was suggested to 
be related to RTK-inhibitor sensitivity in CRC. 
BIBF 1120, another multi-target angiokinase 
inhibitor showed efficacy when combined with 
afatinib against CRC with KRAS mutation in 
vitro [29]. BIBF 1120 also targets FGFR and 
PDGFR, but mainly targets VEGFR, and no pre-
vious studies reported KRAS/BRAF mutant 
CRC and FGFR inhibitor sensitivity. We sur-
mised that KRAS or BRAF mutation status 
might affect FGFR inhibitor - TKI258 - sensitivity 
in CRC.
In this study, to identify better RTK inhibitors 
that can improve CRC treatment, we deter-
mined whether genetic aberration of a novel 
target’s downstream signals might affect the 
efficacy of an RTK inhibitor. First, we hypothe-
sized that inhibition of FGFR will efficiently sup-
press tumor growth in CRC, and then we 
hypothesized that the KRAS and BRAF mutant 
CRC cell lines will exhibit distinct sensitivities to 
the TKI258, which mainly targets FGFR. The 
results of this study could lead to the identifica-
tion of predictive biomarkers and thus facilitate 
the selection of CRC patients who are likely to 
benefit from treatment with the FGFR inhibitor. 
We investigated the anti-tumor activity of 
TKI258 in CRC cell lines carrying KRAS or BRAF 
mutations, in vitro and in vivo, to determine 
whether the sensitivity of these cells to the 
inhibitor depends on specific gene alteration. 
Materials and methods
Cell lines and cell culture
The 6 human CRC cell lines used in this study - 
KM12SM, KM-12L4, Colo320DM, SNU-C4, 
SNU-1235, and SW48 - were with no known 
KRAS or BRAF mutation. And the 10 human 
CRC cell lines with any of KRAS or BRAF muta-
tion used in this study - DLD-1, HCT-15, 
COLO205, SW480, HCT-116, LoVo, WiDr, 
CaCo2, RKO, and HT-29 - were obtained from 
American Type Culture Collection (Bethesda, 
MD). All cell lines were cultured in MEM or 
RPMI-1640 medium supplemented with 10% 
FBS (GIBCO), 100 U/mL penicillin, and 0.1 mg/
mL streptomycin in a humidified 5% CO2 incuba-
tor. Among the 10 CRC cell lines used in this 
study [25, 30, 31], 5 CRC cell lines had only 
KRAS mutations (DLD-1, LoVo, SW480, HCT-15, 
and HCT-116) and 5 CRC cell lines had only 
BRAFV600E mutations (HT-29, COLO205, RKO, 
CaCo2, and WiDr). There were no serum starva-
tion or stimulation throughout the experi- 
ments.
Receptor tyrosine kinase inhibitor
TKI258 (4-amino-5-fluoro-3-[5-(4-metylpipera-
zin-1-yl)-1H-benzimidazol-2-yl] quinolin-2(1H)-
one, formerly known as CHIR258), which tar-
gets FGFRs, PDGFRs, and VEGFRs, was 
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purchased from Eurasian Chemicals Pvt. Ltd. 
We prepared 10 mM stock solutions of the drug 
and stored them at -20°C.
Receptor tyrosine kinase array
To screen for the activity of specific RTKs, we 
used the Human Phospho-RTK Array (R&D 
Systems) according to the manufacturer’s pro-
tocols. Briefly, 300 μg of proteins were added to 
a blocked membrane and incubated at 4°C. 
After washing, horseradish peroxidase (HRP)-
conjugated anti-phosphotyrosine antibodies 
(1:2,000) were added to each membrane and 
incubated. After washing the membranes fur-
ther, proteins were visualized using an enhan- 
ced chemiluminescence (ECL) detection sys-
tem (Amersham). The activated RTK levels were 
quantitated using GenePix Pro 4.1 software 
(Axon Instruments) and normalized using the 
positive control’s intensity in each membrane. 
RTK signal intensity was measured as the dif-
ference between the mean of each RTK’s inten-
sity and mean of negative signal intensity. 
Relative RTK intensity was defined as the RTK 
signal intensity of each sample divided by the 
positive signal intensity of each membrane.
Immunoblotting analysis
Cells were seeded in 6-well plates and incubat-
ed for overnight at 37°C. On the next day, cul-
ture media was replaced with serum-free media 
and the cells were again incubated overnight. 
Cells were then incubated with the drug (1 μM 
TKI258 or PBS control) in serum-free media at 
37°C for indicated times (0, 0.5, 1, 3, and 6 h). 
Cells were lysed in NP-40 lysis buffer and pro-
teins were resolved using 6% or 10% SDS poly-
acrylamide gels and then transferred to PVDF 
membranes (GE Healthcare) by using electrob-
lotting. The following primary antibodies were 
used in the experiments: p-FGFR1 (Y653/
Y654) (Santa Cruz Biotechnology), p-Akt (S473), 
AKT, p-ERK1/2 (T202/Y204), ERK1/2, p-PI3K 
(Y458/Y199), PI3K, p-4EBP1 (Thr37/46), 
4EBP1, p-p70S6K (T389), and p70S6 (Cell 
Signaling). Anti-GAPDH antibody (Abcam) was 
used to control for equal loading.
Cell-viability assay
Cells were seeded in 96-well plates at a density 
of 5,000 cells/well and incubated at 37°C. 
TKI258 was serially diluted using culture media, 
and various concentrations of the drug were 
added to each well and incubated for 3 days. 
MTT (3-(4,5-dimethylthiazol)-2,5-diphenyl tet-
razolium) was then added to the medium for 4 
h, the medium was removed, the precipitate 
was dissolved in DMSO, and the absorbance 
was read at 570 nm. The drug concentrations 
required to inhibit cell growth by 50% (IC50) 
were calculated through interpolation of the 
dose-response curves by using CalcuSyn soft-
ware (Biosoft).
Anchorage-independent colony formation as-
say
We added 0.6% Noble agar (Difco) as a base-
ment into each well of culture plates. After the 
agar solidified, cells (3,000 cells/well) were 
suspended in 0.4% Noble agar mixed in culture 
media containing 10% FBS and plated in tripli-
cate on top of the basement. Plates were incu-
bated at 37°C for 3 weeks and colonies featur-
ing a diameter > 200 μm were counted and 
photographed under an inverted microscope.
Reverse transcription (RT)-PCR analysis
Total RNA was isolated using the Trizol reagent 
(Invitrogen) and cDNAs were synthesized using 
Superscript II Reverse Transcriptase (Invitrogen) 
according to the manufacturer’s instructions. 
RT-PCR reactions were performed using Taq-
Gold DNA polymerase (Invitrogen), and the 
amplified products were separated on ethidium 
bromide gels containing 1.2% agarose. The 
house-keeping gene GAPDH was selected as 
the positive control. The primer set used for 
RT-PCR amplification of the gene encoding 
FGFR1 was the following: forward 5’-CAT CCC 
CAG AAA AGA TGG AA-3’, and reverse 5’-CCT 
CCC CTG TTC CCA TTA CT-3’.
Xenograft study
Female BALB/c nu/nu mice, 6-8-weeks old, 
were implanted subcutaneously with LoVo cells 
(2.0 × 107) or HT-29 cells (1.0 × 107) in the 
flank. Once the tumors could be measured 
(mean tumor volume of 200-300 mm3), the 
mice were assigned to 2 groups, the vehicle 
only group and the TKI258-treated group (n = 4 
per group in the case of LoVo cells; n = 6 per 
group, HT-29 cells). TKI258 was administered 
orally at 70 mg/kg per day for 4 weeks. Tumor 
volumes were measured every other day. After 
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mice were sacrificed, all the organs were thor-
oughly examined, and formalin-fixed paraffin-
embedded tumors were subjected to pathologi-
cal analysis.
Immunohistochemistry (IHC)
Following deparaffinization and rehydration, 
tumor sections were treated with an antigen-
retrieval solution (DAKO). Endogenous peroxi-
dases were quenched using 3% H2O2. Sections 
were stained using antibodies against FGFR1 
(1:50, Abcam), p-ERK (1:50, Cell Signaling 
Technology), p-AKT (1:100, Abcam), CD31 
(1:100, Abcam), and Ki-67 (1:100, DAKO), 
which were diluted in an antibody-dilution buf-
fer (DAKO). Staining was visualized using 
3,3-diaminobenzidinetrahydro chloride (DAB; 
DAKO). Lastly, each slide was counterstained 
with hematoxylin for 5 min, washed with water, 
mounted, and covered with a coverslip.
TUNEL assay
DNA fragments in tissue sections were detect-
ed using a TACS® 2 TdT DAB Kit (Trevigen). 
Figure 1. Differently activated RTKs in 10 CRC cell lines carrying KRAS or BRAF mutation. A. Human phospho-RTK 
array was done among 10 CRC cell lines. Each RTK is spotted in duplicate and positive controls are the pairs of dots 
in each corner. The activated RTK levels were quantitated using GenePix Pro 4.1 software (Axon Instruments) and 
relative RTK intensity was calculated comparing with positive control’s intensity in each membrane. B. Among the 
RTKs tested, the mean values of relative RTK intensity that are the same or > 5.0 are shown on the graph. RTKs 
appeared to be more highly activated in KRAS mutant cell lines than in BRAF mutant cell lines. C. The 8 RTKs that 
were differently activated because of KRAS or BRAF mutation in the CRC cell lines are shown in the table and the 
heat-map. *SW480 carries the KRAS G12V mutation, whereas the other 4 cell lines carry the KRAS G13D mutation.
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Briefly, the enzyme terminal deoxynucleotidyl 
transferase (TdT) was used to incorporate 
digoxigenin-conjugated dUTP at the ends of 
DNA fragments. The signal of TdT-mediated 
dUTP nick-end labeling (TUNEL) was then 
detected using an anti-digoxigenin antibody 
conjugated with peroxidase. TUNEL-positive ce- 
lls were counted in 5 random high-power fields 
per section and are reported as a percentage 
of positive cells in each cellular compartment.
Statistical analysis
The statistical significance of differences 
between 2 groups of data was assessed using 
the unpaired t test in SPSS 21.0 software; a 
p-value of < 0.05 was considered statistically 
significant.
Results
RTK activity in CRC cell lines
To screen for RTK activity in KRAS or BRAF 
mutant 10 CRC cell lines, we used a human 
phospho-RTK array (Figure 1A). In addition to 
highly activated EGFR, several other druggable 
targets such as ErbB2, HGF-R, IGF-IR, FGFR1, 
FGFR3, and VEGFR3 were also highly activated 
in CRC cell lines. Various RTKs were more acti-
vated in the KRAS mutant cell lines than in the 
BRAF mutant cell lines (Figure 1B). Specifically, 
EphA7, Mer, TrkA, and FGFR1 appeared to be 
Figure 2. Anti-tumor effect of TKI258 toward CRC cell lines. The growth inhibitor activity of TKI258 toward CRC cell 
lines was determined by the cell-viability assay (MTT Assay) after 72 hours of continuous drug exposure. IC50 values 
were calculated (A). CRC cell lines without any of KRAS or BRAF mutation (KRASwt BRAFwt) were more sensitive to 
TKI258. There was a trend toward KRAS mutant CRC cell lines being more sensitive to TKI258 compared to BRAF 
mutant (IC50 (nM): KRAS mutant cell lines: 1274.6 ± 1015.9; BRAF mutant cell lines: 1727.6 ± 867.5) (B). 
Figure 3. FGFR1 expression among CRC cell lines. 
We compared FGFR1 mRNA, protein level and its ac-
tivity among CRC cell lines, via RT PCR and Western 
blot. FGFR1 was relatively over-expressed among 
KRAS mutant CRC cell lines (DLD-1, LoVo, SW480, 
HCT-116, and HCT-15) compared to BRAF mutant 
(WiDr, COLO205, RKO, CaCo2, and HT-29). P-FGFR1 
activities of KRAS mutant LoVo cell line and BRAF 
mutant HT-29 cell line were similar. *SW480 had 
KRAS G12V mutation, while other 4 cell lines have 
KRAS G13D mutation.
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relatively more activated in KRAS mutant cell 
lines, whereas EphB2, Insulin R, IGF-IR, and 
VEGFR3 were relatively more activated in BRAF 
mutant cell lines (Figure 1C). Because FGFR is 
considered one of the potential targets in CRC, 
our results demonstrating that FGFR1 and 
FGFR3 are highly activated in CRC cell lines pro-
vides a strong rationale for treating CRC with an 
FGFR inhibitor.
TKI sensitivity based on genetic variations
Because TKI258 is an ATP-competitive inhibitor 
belonging to Class III–V RTK inhibitors that are 
especially sensitive against FGFRs (FGFR1/2/3, 
with kinase IC50 values of 8-13/21/9-18 
nmol/L, respectively [32, 33]), we used TKI258 
as a novel tyrosine kinase inhibitor (TKI) to 
inhibit FGFRs in CRC. First, to test whether the 
KRAS or BRAF mutation status affected cell 
viability in response to the FGFR inhibitor, we 
measured the anti-tumor activity of TKI258 
against 16 CRC cell lines (6 KRASwt BRAFwt, 5 
KRAS mutant cell lines, and 5 BRAF mutant cell 
lines) (Figure 2). CRC cell lines without any of 
KRAS or BRAF mutation (KRASwt BRAFwt) were 
more sensitive to TKI258. We could not tell 
whether KRAS or BRAF mutation decides sensi-
tivity to TKI258 with this MTT assay result, but 
there was trend toward KRAS mutant CRC cell 
Figure 4. In vitro anti-tumor effect of TKI258 in 
LoVo and HT-29 cells. A. The GroCell-viability as-
say (MTT Assay) was performed using the multi-
target FGFR inhibitor, TKI258. The KRAS mutant 
LoVo cells (IC50 = 130 nM) were more sensitive 
to TKI258 than the BRAF mutant HT-29 cells 
(IC50 = 2,530 nM). B, C. Anchorage-independent 
colony-formation assay performed using TKI258 
to compare LoVo and HT-29 cell lines. Almost no 
colonies were formed by the KRAS mutant LoVo 
cells after adding 500 nM TKI258, and the re-
sult was statistically significant; by contrast, the 
BRAF mutant HT-29 cell line was not affected by 
the drug treatment. *p < 0.05.
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lines being more sensitive to TKI258 compared 
to BRAF mutant (IC50 (nM): KRAS mutant cell 
lines: 1274.6 ± 1015.9; BRAF mutant cell lines: 
1727.6 ± 867.5). Immortalized normal cell lines 
(CCD-841COTR and CCD-18CO) were more 
resistant than CRC cell lines (IC50 of 5000 nM, 
data not shown on figure).
We compared FGFR1 mRNA and protein levels 
and FGFR1 activity among the CRC cell lines by 
using RT-PCR and western-blotting analyses; 
FGFR1 is considered the major target of 
TKI258. There were no correlation of phosphor-
ylated FGFR1 level and sensitivity to TKI258 
measured by MTT assay. The LoVo (KRASG13D 
BRAFwt) and HT-29 (KRASwt BRAFV600E) cell lines 
were chosen because phosphorylated FGFR1 
was similarly overexpressed in these cells 
(Figure 3). Assays to determine in vitro anti-
tumor effect of TKI258 against LoVo (KRASG13D 
BRAFwt) and HT-29 (KRASwt BRAFV600E) cell lines 
are performed. Both cell lines showed a dose-
dependent inhibition of cell growth in cell-viabil-
ity assays (Figure 4A). Whereas LoVo cells were 
highly sensitive to TKI258 (IC50 of 130 nM), 
HT-29 cells were relatively more resistant to 
TKI258 treatment (IC50 of 2,530 nM). When we 
used the soft agar colony-formation assays to 
evaluate the anchorage-independent in vitro 
anti-tumor activity of TKI258 (Figure 4B, 4C), 
almost no colony was formed in the case of the 
KRAS mutant LoVo cell line after adding 500 
nM TKI258. However, the BRAF mutant HT-29 
cells were resistant to TKI258 and showed only 
3% reduction in colony formation relative to 
control.
Figure 5. Changes in downstream signaling molecules after TKI258 treatment in LoVo and HT-29 cells. KRAS mu-
tant LoVo and BRAF mutant HT-29 cells were treated with 1 μM TKI258 in vitro to evaluate the time-dependent ef-
fect on downstream signaling molecules by using western-blotting analysis. PI3K-AKT and RAS-RAF-ERK pathways 
appeared to be inhibited by TKI258 in LoVo cells, but the PI3K-AKT pathway was not inhibited in HT-29 cells and, 
in these cells, the RAS-RAF-ERK pathway appeared to be activated. (24 hour treatment data not shown, since cells 
were damaged due to long serum free status).
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Changes in downstream signaling following 
TKI258 treatment
To evaluate how downstream signaling mole-
cules are affected after drug treatment in time-
course, LoVo and HT-29 cells were treated with 
1 μM TKI258 in vitro and then examined using 
western-blotting analysis (Figure 5). TKI258 sh- 
owed profound, sustained inhibition of FGFR1 
phosphorylation after 30-min treatment in the 
KRAS mutant LoVo cells, but not in the BRAF 
mutant HT-29 cells. In HT-29 cells, FGFR1 app- 
eared to show increased and sustained activa-
tion after 30 min of TKI258 treatment. Analyzing 
the PI3K-AKT signaling pathways revealed that 
TKI258 treatment reduced the levels of phos-
phorylated PI3K, AKT, and P70S6K without 
altering the levels of phosphorylated 4EBP1 or 
the total expression of 4EBP1 in LoVo cells; 
however, no alteration in downstream signaling 
molecules was detected in HT-29 cancer cells. 
By contrast, TKI258 treatment increased the 
level of activated ERK in both LoVo and HT-29 
cells.
In vivo efficacy and pharmacodynamic marker 
evaluation using TKI258
To evaluate the anti-tumor effect of TKI258 in 
vivo, a daily oral dose of TKI258 of 70 mg/kg 
was administered to mice bearing subcutane-
ous LoVo or HT-29 human tumor xenografts. 
Contrasting the in vitro results, no difference in 
in vivo anti-tumor effect was observed between 
the 2 xenograft models featuring distinct muta-
tion statuses: TKI258 delayed tumor growth 
equally in both cell lines compared with the 
control group (Figure 6). No major toxicity was 
detected in the treated mice in both groups, 
and the bodyweights of these mice were not 
different (data not shown).
Next, when we evaluated the pharmacodynam-
ics of target modulation in the tumors (Figure 
7), TKI258 treatment was found to substantial-
ly reduce the levels of phosphorylated FGFR1 in 
both xenografts. Cells positive for phosphory-
lated AKT were not markedly reduced after the 
treatment, but cells positive for phosphorylated 
Figure 6. In vivo anti-tumor effect of TKI258 in LoVo and HT-29 xenograft models. (A, B) After treating with the 
TKI258 (70 mg/kg/d PO for 4 weeks), the in vivo xenograft model showed that TKI258 delayed the growth of tumors 
induced by both cell lines compared with the control group (shown as Mean ± SE). However, when we precisely mea-
sured the differences in tumor volume in the control and drug-treated groups in a time-dependent manner, HT-29 
xenografts appeared to be inhibited earlier than LoVo xenografts. Compared with the control groups, in the LoVo 
and HT-29 cell lines, tumor volume (C) and weight (D) decreased similarly following treatment with TKI258 in vivo.
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ERK were reduced in the TKI258-treated group. 
This result differed from the in vitro western-
blotting data, which showed that p-ERK stain-
ing was not reduced. Large areas of necrosis 
were also detected in TKI258-treated tumors 
when compared with control tumors. When 
CD31 was stained to evaluate the anti-angio-
genic activity of TKI258 in vivo, the size and 
numbers of CD31-positive blood vessels within 
the tumors were observed to be diminished 
after the treatment in both xenografts. 
Furthermore, actively proliferating tumor cells 
that were identified using Ki-67 staining were 
markedly reduced in TKI258-treated mice. 
Moreover, the TUNEL assay used to assess the 
effect of TKI258 on apoptosis showed no 
change in the apoptotic index in either xeno-
graft (Figure 8). These results suggest that 
TKI258 inhibited tumor growth in vivo and that 
the effect of TKI258 in target-molecule inhibi-
tion was similar in KRAS mutant and BRAF 
mutant cell lines. Taken together, our results 
suggest that the KRAS and BRAF mutation sta-
tus does not affect tumor-growth inhibition and 
changes in target molecules induced by the 
FGFR inhibitor in vivo.
Discussion
Numerous RTK inhibitors are currently avail-
able that target various cancers and these 
inhibitors are continuing to show clinical suc-
cess in various cancer treatments. To treat 
metastatic CRC, anti-EGFR monoclonal anti-
bodies such as cetuximab and panitumumab 
and anti-angiogenic agents such as bevacizum-
ab and regorafenib are becoming widely used. 
However, because certain disappointing results 
such as drug resistance have been obtained, 
more effective RTK targets are sought for CRC 
treatment.
We screened 10 KRAS or BRAF mutant CRC 
cell lines using an RTK array to evaluate which 
RTKs are up-regulated and to check for novel 
target-RTK candidates. EGFR was the single 
most activated RTK, and we also detected 
other activated RTKs such as HGFR, ErbB2, 
Figure 7. Immunohistochemical staining of human colon tumor xenografts. Tumors were resected and processed 
and slides were stained using antibodies against p-FGFR1, p-ERK, p-AKT, and CD31. H&E staining was also per-
formed. TKI258 treatment reduced the staining for p-FGFR1, p-ERK, and CD31 in tumor xenografts induced by both 
cell lines. However, p-AKT stained tumor cells were similar in the control and treated groups. Large areas of necrosis 
were also detected using H&E staining in the TKI258-treated tumors when compared with the control tumors (A: 
LoVo; B: HT-29). All magnifications 400×, except H&E magnification (40×); N = massive necrosis; V = viable tumor.
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FGFR1, FGFR3, and VEGFR3, which already 
have inhibitors being used in other types of 
cancer treatment. Certain RTKs showed vary-
ing activity patterns according to KRAS or BRAF 
mutation status: EphA7, Mer, TrkA, and FGFR1 
were highly activated in 5 KRAS mutant cell 
lines, and EphB2, Insulin R, IGF-IR, and VEGFR3 
were highly activated in 5 BRAF mutant cell 
lines. Among these RTKs, although EphA7 and 
EphB2 belong to the same ephrin-receptor fam-
ily, EphA7 was markedly upregulated in KRAS 
mutant cell lines and EphB2 was upregulated in 
BRAF mutant cell lines. Ephrin-family proteins 
are known to affect cytoskeletal and cell-adhe-
sion mechanisms and thus regulate cell posi-
tion and motility. Interestingly, EphA7, which 
acts as a tumor suppressor in follicular lympho-
ma [34], was reported to be down-regulated in 
CRC relative to normal tissue [35]. The finding 
for VEGFR3 is also surprising since VEGFR3 is 
generally associated with lymphangiogenesis. 
The clinical relevance of these findings in rela-
tion to KRAS or BRAF mutation status of CRC 
remains unknown and further studies are 
warranted.
FGFR is one of the RTKs that plays key biologi-
cal roles in cancer, and FGFR has emerged as a 
potential therapeutic target [36-38]. Recently, 
FGFR1, FGFR2, or FGFR3 overexpression in 
CRC was reported to result in increased growth 
and invasion in preclinical or clinical settings 
[13, 15, 16, 39]. In this study, 10 CRC cell lines 
we tested showed overexpressed FGFRs (rela-
tive RTK intensity among KRAS-mutant cell 
lines: FGFR1 > FGFR3 > FGFR2α; and among 
BRAF-mutant cell lines: FGFR3 > FGFR1 > 
FGFR2α; almost no FGFR4 was detected in 
either cell line); this result identifies FGFR as a 
potential target in CRC treatment. Moreover, 
considering that tumor progression is mediated 
not only by the malignant cancer cells them-
selves but also by surrounding non-malignant 
stromal cells such as fibroblasts, FGFR is con-
sidered an attractive candidate target and sev-
eral drugs against this RTK family are being 
developed. Because the initiation and progres-
sion of most cancers rarely depend on a single 
growth factor or a simple genetic alteration, 
multi-target RTK inhibition might represent an 
alternative strategy to inhibit complex signaling 
Figure 8. Ki-67 staining and TUNEL assay of xenograft models. Ki-67 staining and TUNEL assay were also performed 
(A). TKI258-treated mice showed a significant reduction of Ki-67-positive cells in tumors induced by both cell lines 
(B), but the numbers of TUNEL-positive cells were not statistically different (C). *P < 0.05.
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pathways in cancer cells, even if increased tox-
icity is occasionally detected. Herein, we have 
described the anti-tumor activities of TKI258, a 
multi-target angiokinase inhibitor, by inhibiting 
Class III, IV, and V RTKs, notably those of the 
FGFR, VEGFR, and PDGFR subfamilies. 
We evaluated 16 CRC cell lines for their sensi-
tivity to TKI258 in relation to the KRAS or BRAF 
mutation status. Our in vitro data showed that 
TKI258 exhibited significant anti-tumor activity 
against CRC cell lines without any of KRAS or 
BRAF mutation, compared to CRC cell lines 
with any of KRAS or BRAF mutation. Among 
KRAS or BRAF mutant CRC cell lines, it was 
hard to tell which mutation type was more sen-
sitive to TKI258, but there was trend toward 
KRAS mutant CRC cell lines being more sensi-
tive. In KRAS mutant HT-29 cells, TKI258 inhib-
ited PI3K-AKT activities, whereas these activi-
ties in BRAF mutant LoVo cells were not 
affected by the treatment. ERK appeared to be 
activated in both cell lines after treatment with 
TKI258, which suggests that KRAS or BRAF 
mutation leading to the activation of the RAS-
RAF-MAPK pathway might function as a resis-
tance mechanism against the FGFR inhibitor. 
Studies conducted using EGFR inhibitors also 
suggested that drug resistance results from 
the KRAS mutation directly activating RAS-RAF-
MAPK downstream signaling [40, 41]. Inter- 
estingly, ERK activation peaked at 1 hour after 
treatment and then appeared to diminish in 
LoVo cells, where p-ERK levels increased in a ti- 
me-dependent manner in HT-29 cells. TKI258’s 
ability to inhibit multiple angiokinases might 
have played a role here. For instance, initial 
inhibition of FGFR by the drug might have 
blocked the PI3K-AKT pathway but activated 
the RAS-RAF-MAPK pathway, and the sequen-
tial delayed effects of PDGFR or VEGFR inhibi-
tion might have influenced RAS-RAF pathway to 
inactivate ERK subsequently. Conversely, be- 
cause KRAS functions not only through the 
RAS-RAF-MAPK pathway but also through mul-
tiple effector-mediated cytoplasmic signaling 
networks including the PI3K pathway [42], inhi-
bition of the PI3K pathway by the drug might 
have subsequently affected RAS-RAF-MAPK 
signaling in KRAS mutant cells. Following 
TKI258 treatment in the BRAF mutant HT-29 
cells, an up-regulation of p-ERK was detected, 
whereas p-PI3K and p-AKT were repressed. 
Previously, anchorage-independent growth and 
tumorigenic growth of BRAF mutation-positive 
CRC cells were shown to depend on the func-
tion of the mutant BRAF and to depend criti-
cally on persistent ERK activation [43]. 
Furthermore, TKI258 might have not altered 
PI3K pathway in the BRAF mutant HT-29 cells 
because HT-29 cell lines are known to carry a 
PI3K-activating E545K mutation, whereas LoVo 
cells do not exhibit any PI3K mutation.
Because our in vitro data revealed that LoVo 
cell lines were more sensitive than HT-29 cell 
lines to TKI258, we expected tumors generated 
by implanted LoVo cells to have regressed more 
than tumors generated by the HT-29 cells. 
However, relative to control, both of the xeno-
grafts tested in our study exhibited a significant 
reduction in tumor growth regardless of the 
KRAS or BRAF mutation status. Our IHC results 
were also distinct from the in vitro immunoblot-
ting results after TKI258 treatment: p-ERK-pos-
itive cells were reduced but p-AKT-positive cells 
were similar in both xenografts, whereas the in 
vitro study showed increased p-ERK in both cell 
lines but reduced p-AKT in the LoVo cell line 
considering the crosstalk between the path-
ways, resulting in drug resistance. Recently, 
concomitant AKT/mTOR inhibition was suggest-
ed to be required for BRAF-mutant CRC [44], 
and we could talk into account including an 
mTOR inhibitor as a combination partner in fur-
ther studies. Treatment with the FGFR inhibitor 
has been reported to reduce Ki67 staining and 
increase TUNEL staining in prostate cancer 
cells and head and neck cancer cells, implying 
that the inhibitor not only suppressed cell prolif-
eration but also induced apoptosis [45, 46]. In 
our result, TKI258 treatment inhibited cell pro-
liferation and angiogenesis but did not induce 
apoptosis. This disparity could be explained 
related to apoptosis induction as the distinct 
origins of the tumor and the inhibition of differ-
ent subclasses of FGFRs.
One explanation of the in vitro and in vivo differ-
ences might be from the innate difference of 
two systems including the delayed effect of the 
drug, because we used a 4-week treatment in 
the xenograft study. Another possible explana-
tion is the ability of TKI258 to target multiple 
RTKs and its effect on the tumor microenviron-
ment: TKI258 targets not only FGFRs but also 
VEGFR and PDGFR. A key factor of the tumor 
microenvironment is an abnormal but abun-
dant vasculature, which supplies sufficient nu- 
trients and oxygen for sustenance and ensures 
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tumor progression [47]. The VEGFR-inhibiting 
feature of the multi-target inhibitor TKI258 
might play a critical role in equally suppressing 
proliferation of both KRAS and BRAF mutated 
tumor cells in vivo; we observed that CD31-
stained vessel size and numbers were dimin-
ished after treatment with TKI258. In addition, 
not only VEGFR but also FGFR signaling potent-
ly affects the microenvironment, because one 
of the well-known direct effects of FGF signal-
ing is the promotion of angiogenesis through 
endothelial cells and other vascular cells [48]. 
Hence, TKI258 will show anti-angiogenic effect 
not only by inhibiting VEGFRs, but also by inhib-
iting FGFRs.
FGF and FGFRs are considered to act synergis-
tically with the VEGF pathway to promote neo-
vascularization, implying one mechanism of 
adaptive resistance to VEGF inhibitor at least in 
renal cell carcinoma or pancreatic cancer [49]. 
Because EGFR and VEGF inhibitors are the only 
approved RTK inhibitors widely used to treat 
CRC, TKI258 targeting FGFRs might show prom-
ising results among CRC patients who are 
refractory to EGFR or VEGF inhibitors. Previously, 
LoVo and HT-29 cells were reported to be resis-
tant to the EGFR inhibitor cetuximab in vivo 
[50]. However, our results showing that these 
cell lines are sensitive to TKI258 suggest that 
the resistance to the EGFR inhibitor might be 
overcome by using TKI258.
Our results indicate that treatment with the 
multi-target angiokinase inhibitor TKI258 was 
effective in KRAS mutant LoVo cells but not in 
BRAF mutant HT-29 cells in vitro. However, our 
in vivo studies showed that KRAS and BRAF 
mutant xenograft tumors were both inhibited by 
TKI258 treatment, which might have resulted 
from the angiogenesis-suppressing effect of 
the multi-target inhibitor TKI258. Moreover, our 
results revealed the possibility of using TKI258 
to overcome resistance to EGFR or VEGF inhibi-
tors in CRC. The results relating to the in vivo 
effect of the drug would be more compelling if 
further studies with more cell lines were con-
ducted. In conclusion, FGFR is an effective tar-
get for CRC treatment regardless of KRAS or 
BRAF mutation and our results suggest that 
combined targeting of multiple RTKs, especially 
FGFR and VEGFR, might be a novel approach to 
improve the outcome of CRC patients, possibly 
among selected patients in whom FGFR is over-
expressed or amplified. 
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